[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648028":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":25,"responsibleParty":35,"collaborators":25,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":25,"enrollmentInfo":46,"targetDuration":25,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":60,"whyStopped":25,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":25},{"fullName":5,"class":6},"Clinique du Sport, Bordeaux Mérignac","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Bone marrow-derived PRP","EXPERIMENTAL","Participants receive a platelet-rich plasma (PRP) injection prepared from bone marrow aspirate obtained from the posterior iliac crest. After processing, the PRP is injected under ultrasound guidance into the affected lateral elbow tendon.",[13],"Procedure: Bone Marrow-Derived PRP",{"label":15,"type":16,"description":17,"interventionNames":18},"Peripheral blood-derived PRP","ACTIVE_COMPARATOR","Participants receive a platelet-rich plasma (PRP) injection prepared from peripheral venous blood. After processing, the PRP is injected under ultrasound guidance into the affected lateral elbow tendon.",[19],"Procedure: Peripheral Blood-Derived PRP",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"PROCEDURE","Bone Marrow-Derived PRP",[9],null,{"type":22,"name":27,"description":17,"armGroupLabels":28,"otherNames":25},"Peripheral Blood-Derived PRP",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Marion Mandon, PhD","CONTACT","+336 78 27 76 72","drc@vivalto-sante.com",{"type":36,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100648028","feasibility-and-efficacy-of-bone-marrow-prp-injection-in-refractory-fissure-tendinopathies-of-the-lateral-epicondylar-tendons-100648028",false,"NCT07717203","Feasibility and Efficacy of Bone Marrow PRP Injection in Refractory Fissure Tendinopathies of the Lateral Epicondylar Tendons","EPI-PRP","Inclusion Criteria:\n\n* Diagnosis of chronic lateral epicondylitis with partial-thickness tendon tear of the common extensor tendon confirmed by ultrasound.\n* Symptoms persisting despite appropriate conservative treatment for at least 3 months.\n* Indication for platelet-rich plasma (PRP) injection established by the treating physician.\n* Ability to understand the study procedures and comply with follow-up requirements.\n* Written informed consent obtained prior to participation.\n* Affiliation to a health insurance system (as required by French regulations).\n\nExclusion Criteria:\n\n* Full-thickness tear of the common extensor tendon.\n* Previous surgery of the affected elbow.\n* PRP injection in the affected elbow within the previous 6 months.\n* Corticosteroid injection in the affected elbow within the previous 3 months.\n* Current treatment with medications incompatible with PRP preparation according to study procedures.\n* Active infection at the injection site or systemic infection.\n* Known hematologic disorder affecting platelet function or coagulation.\n* Current anticoagulant therapy that cannot be interrupted according to study requirements.\n* Pregnancy or breastfeeding.\n* Participation in another interventional clinical trial that could interfere with study outcomes.\n* Any medical, psychiatric, or social condition that, in the investigator's opinion, could compromise participant safety or compliance with study procedures.","ALL","18 Years",{"count":47,"type":48},24,"ESTIMATED","INTERVENTIONAL",[51],"NA","Lateral epicondylitis with tendon tear resistant to conservative treatment remains a common clinical condition with limited therapeutic options before surgery is considered.\n\nPlatelet-rich plasma (PRP) injections are used in tendinopathies because of their potential regenerative properties. More recently, platelet-rich plasma derived from bone marrow aspirate (bone marrow-derived PRP) has emerged as an alternative source of platelets and bioactive factors. However, the clinical implications of its different biological composition compared with peripheral blood-derived PRP remain poorly understood.\n\nThis monocentric randomized pilot trial aims to assess the feasibility of the intervention and to estimate the effect of bone marrow-derived PRP compared with peripheral blood-derived PRP in patients with resistant partial-thickness lateral epicondylar tendinopathy.\n\nParticipants will be randomly assigned in a 1:1 ratio to receive either bone marrow-derived PRP or peripheral blood-derived PRP injection. Clinical outcomes, pain, functional scores, imaging findings, safety, and feasibility parameters will be assessed over a 12-month follow-up period.\n\nThe study is not powered to demonstrate superiority between treatments but is intended to generate preliminary effect estimates and feasibility data for the design of a future confirmatory trial.",[54],"Epicondylitis, Lateral",[56,57,58,59],"bone marrow concentrate","Platelet rich plasma","fissure","tendon","NOT_YET_RECRUITING","2026-07-16",{"date":63,"type":64},"2026-07-21","ACTUAL",{"date":66,"type":48},"2026-09",{"date":68,"type":48},"2029-03",{"name":5,"class":6}]